Posted on 10/12/2009 in Pharmaceutical Company Product News
Amgen has revealed the results of a study into Nplate (romiplostim) - its therapy designed for children with chronic immune thrombocytopenic purpura (ITP).
The results showed that treatment with Nplate appeared to be generally well-tolerated compared to placebo in youngsters aged between 12 months to 18 years old with chronic ITP.
Adverse events for the two treatments respectively occurred in 18 per cent of those being treated with Nplate and 20 per cent of those administered a placebo drug.
"This is the first study of an agent that stimulates platelet production in the paediatric population," stated Dr George Buchanan, professor of paediatrics at the University of Texas Southwestern Medical Centre.
He added that the data suggests that Nplate could represent an integral treatment option for some children suffering from the condition.
In other Amgen news, the firm announced last month that it had won the accolades Best Pipeline and Best New Drug for Nplate at the Scrip Awards last month.
